Andrew Darlington, DO
Advanced Heart Failure and Transplant Cardiology · Fayetteville, GANPI 1942352851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $761,565 of the $1,002,905 with a category attached, or 75.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.7%. Among advanced heart failure and transplant cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,329 payments — averaging $754.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$198K
- Akcea Therapeutics, Inc.$157K
- E.r. Squibb & Sons, L.L.C.$121K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$117K
- Pfizer$106K
- Merck$106K
- plus $199K from 30 others
Across 24 payments — averaging $2904.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$31K
- American Regent$31K
- Ionis Pharmaceuticals, Inc.$7K
- Boehringer Ingelheim$750
What the payments were for
- Consulting fees$73,0107%
- Speaking & faculty fees$761,56576%
- Travel & lodging$143,00114%
- Food & beverage$24,9792%
- Education$3500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 237 | $197,878 |
| Akcea Therapeutics, Inc. | 214 | $157,385 |
| E.r. Squibb & Sons, L.L.C. | 123 | $120,675 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 128 | $116,593 |
| Pfizer | 107 | $106,108 |
| Merck | 125 | $105,721 |
| Novartis | 87 | $69,365 |
| Scpharmaceuticals Inc. | 26 | $34,881 |
| Lexicon Pharmaceuticals, Inc. | 41 | $30,479 |
| Alnylam Pharmaceuticals Inc. | 41 | $26,080 |
| Bridgebio Pharma, Inc. | 33 | $17,897 |
| Bayer | 27 | $13,349 |
| Vifor Pharma, Inc. | 2 | $2,375 |
| Medtronic | 8 | $910 |
| Actelion Pharmaceuticals US, Inc. | 36 | $820 |
| Abbott | 18 | $454 |
| Novo Nordisk | 16 | $336 |
| Cvrx, Inc. | 11 | $323 |
| Boehringer Ingelheim | 15 | $311 |
| Impulse Dynamics (USA) Inc. | 2 | $195 |
| Analog Devices Inc. | 3 | $153 |
| Shockwave Medical, Inc | 1 | $103 |
| Johnson & Johnson | 8 | $102 |
| Amgen | 5 | $84 |
| Amarin Pharma, Inc. | 2 | $48 |
| United Therapeutics Corporation | 2 | $48 |
| Sobi, Inc | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kls-martin L.p. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$175,934
- TEGSEDI$146,743
- WAINUA$135,982
- CAMZYOS$118,418
- LifeVest$114,753
- VYNDAQEL$105,040
- ENTRESTO$68,369
- FARXIGA$55,384
- FUROSCIX$34,642
- Inpefa$29,623
- Attruby$17,583
- Kerendia$12,817
- AMVUTTRA$9,262
- ONPATTRO$9,227
- Veltassa$2,375
- OPTIMIZER$338
- Barostim Neo System$172
- Sensinel CPM Wearable$108
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$103
How this compares
$1,002,905 in reported general payments places this provider in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 228 | $5,880,484 |
| WainuaEplontersen Sodium | 27 | $1,162,181 |
| EntrestoSacubitril/Valsartan | 1,014 | $1,076,305 |
| EliquisApixaban | 795 | $681,042 |
| FarxigaDapagliflozin Propanediol | 609 | $572,331 |
| JardianceEmpagliflozin | 452 | $497,131 |
| CamzyosMavacamten | 52 | $432,721 |
| VyndaqelTafamidis Meglumine | 14 | $312,652 |
| OpsumitMacitentan | 21 | $267,327 |
| UptraviSelexipag | 11 | $240,486 |
| XareltoRivaroxaban | 206 | $177,804 |
| VerquvoVericiguat | 51 | $54,428 |
| Repatha SureclickEvolocumab | 17 | $18,040 |
| DapagliflozinDapagliflozin Propanediol | 33 | $15,830 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $14,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $106,108 | $6,874,1781,037 claims |
| AstraZenecaWainua, Farxiga, Lokelma | $197,878 | $1,748,623647 claims |
| NovartisEntresto | $69,365 | $1,076,3051,014 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $820 | $507,81332 claims |
| Boehringer IngelheimJardiance | $311 | $497,131452 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $120,675 | $432,72152 claims |
| Johnson & JohnsonXarelto | $102 | $177,804206 claims |
| MerckVerquvo | $105,721 | $54,42851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
Other advanced heart failure and transplant cardiology in Fayetteville
- David MarkhamFayetteville$6K
- Sushee GaddeFayetteville$5K
- Catherine MartiAthens$343K
- Darshak KariaAugusta$296K
- Ugochukwu EgolumGainesville$235K
- Abdul Latif BikakMarietta$214K
- Robert ColeAtlanta$213K
- Nikolas KrishnaMarietta$124K
- Brian HowardMarietta$99K
- Alanna MorrisGainesville$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.